 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRASAs of the April 25, 2023 data cut-off date, among the 22 evaluable...

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several...

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc.(Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, todayannounced the appointment of Megan Filoon as General and Dr. Thian Kheoh as Senior Vice President...

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

BOSTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer...

Elicio Therapeutics Reports Inducement Grants

ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCOAMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger becoming a publicly traded company on Nasdaq Anticipate releasing additional AMPLIFY-201 clinical data in second half 2023 BOSTON, Aug. 11, 2023 (...

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

AMP-CpG directed vaccine to lymph nodes inducing broad humoral and cellular immunity against multiple viral determinants expressed during the EBV life cycle AMP-CpG immunization generated persistent EBV-specific neutralizing antibodies and robust polyfunctional EBV-specific CD4+ and CD8+ T cells ...

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model

Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchangePositive Phase 1 clinical data was recently presented at ASCO 2023 for the 2-peptide formulation of Elicios lead program, ELI-002, the first and only lymph node-targeted mutant KRAS (mKRAS) immunotherapy ...

Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust mKRAS-specific T cell responses induced in 87% of patients BOSTON, June 03, 2023 (GLOBE ...

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the grant of an inducement award to the Companys newly appointed Chief Financial Officer, ...

Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Boston, MA.

Watchers	127
52-Wk Low	$7.21
52-Wk High	$24.39

Market Cap	$66.94M
Volume (M)	2,695.00
52-Wk High	$24.39
52-Wk Low	$7.21

ELTX Elicio Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals